VI UTVECKLAR SYSTEM FÖR SPECIALISTSJUKVÅRD

Impact of short periods with worsened or improved INR control on life expectancy and QALYs in patients with atrial fibrillation.

Lesen, E., et al. (2014). "Impact of short periods with worsened or improved INR control on life expectancy and QALYs in patients with atrial fibrillation." Thromb Res.

            INTRODUCTION: Warfarin-treated patients with poor international normalized ratio (INR) control, measured with time in therapeutic range (TTR) or the standard deviation of transformed INR (SDTINR), have an increased risk for clinical events. To what extent only a short period with an altered INR control may influence outcomes remains unknown. This study assessed the impact of transient periods of worsened or improved INR control on life expectancy and quality-adjusted life years (QALYs) among warfarin-treated patients with atrial fibrillation (AF) using both metrics. MATERIALS AND METHODS: Warfarin-treated patients with AF, registered in the patient record system Journalia during years 1985-2000, were included. Information on all-cause mortality was collected from the Cause of Death Register. Hypothetical scenarios where patients were assumed to have a transiently altered INR control during 30days were modeled statistically using hazard functions, and the impact on remaining life expectancy and QALYs was assessed. RESULTS: When using SDTINR, a 70-year old man within the 20th best INR control percentile was estimated to lose 7.4days of life or 0.0100 QALYs from a 30-day long worsened INR control to that of an average 70-year old male patient. Correspondingly, 4.0days of life or 0.0059 QALYs would be gained if a 70-year old man within the 20th worst INR control percentile would have an average INR control during 30days. The magnitudes were smaller when TTR was used to determine INR control. CONCLUSIONS: Even short periods of an altered INR control is expected to have impact on life expectancy and QALYs among patients with AF.



 



Bilaga
Access this URL (http://www.ncbi.nlm.nih.gov/pubmed/24767952)247679520 kB

Kontakta Journalia

Journalia AB
Tel 0554 - 222 31
Gunnerud 77
686 96 ÖSTRA ÄMTERVIK

Vår support är redo att hjälpa till när det behövs

Öppet kl 08.00-17.00, måndag-fredag

Ring oss på 0554-222 31

E-post